Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study

BACKGROUND: Ipragliflozin is a sodium-glucose co-transporter 2 inhibitor that can improve glycemic control and reduce body weight and blood pressure in patients with type 2 diabetes mellitus (T2DM). We evaluated the efficacy and safety of ipragliflozin in the real-world clinical setting, with a focu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Med Res
Glavni autori: Iizuka, Takashi, Iemitsu, Kotaro, Takihata, Masahiro, Takai, Masahiko, Nakajima, Shigeru, Minami, Nobuaki, Umezawa, Shinichi, Kanamori, Akira, Takeda, Hiroshi, Kawata, Takehiro, Ito, Shogo, Kikuchi, Taisuke, Amemiya, Hikaru, Kaneshiro, Mizuki, Mokubo, Atsuko, Takuma, Tetsuo, Machimura, Hideo, Tanaka, Keiji, Asakura, Taro, Kubota, Akira, Aoyagi, Sachio, Hoshino, Kazuhiko, Ishikawa, Masashi, Matsuzawa, Yoko, Obana, Mitsuo, Sasai, Nobuo, Kaneshige, Hideaki, Minagawa, Fuyuki, Saito, Tatsuya, Shinoda, Kazuaki, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
Format: Artigo
Jezik:Inglês
Izdano: Elmer Press 2016
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701067/
https://ncbi.nlm.nih.gov/pubmed/26767080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2417w
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items